Peter Lynch · Growth at a reasonable price (GARP)
Is Regeneron Pharmaceuticals, Inc. (REGN) a Peter Lynch Stock?
Does not fit Lynch's GARP criteria, growth too low or price too high.
24/100
Não encaixa
3/6 critérios atendidos
Os critérios de Peter Lynch, aplicados a REGN
PEG ≤ 1.0
chave-
EPS CAGR ≥ 15%
chave-13.3%
Revenue CAGR ≥ 10%
-2.8%
Net margin > 0
29.6%
Como REGN pontua em outras estratégias
Dados financeiros ao vivo
Cap. de mercado
$75.69B
P/L (TTM)
16.4x
ROIC (TTM)
8.53%
Margem bruta
84.55%
Outras análises Peter Lynch
Perguntas frequentes
What is REGN's Peter Lynch fit score?
REGN scores 24/100 on our Peter Lynch fit engine. Does not fit Lynch's GARP criteria, growth too low or price too high.
Does Peter Lynch actually own REGN?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends REGN.
How often is this score updated?
REGN's Peter Lynch fit score is recomputed daily from the latest TTM financials. The page below shows when it was last refreshed.
Ferramenta educacional, não é consultoria de investimento. As pontuações são calculadas a partir de dados financeiros públicos contra os critérios publicados de cada estratégia de investimento. Não afirmamos que Peter Lynch possua ou recomende REGN pessoalmente.
